ValuEngine lowered shares of Ohr Pharmaceuticals (NASDAQ:OHRP) from a sell rating to a strong sell rating in a report published on Friday morning.

OHRP has been the topic of several other research reports. Roth Capital initiated coverage on Ohr Pharmaceuticals in a report on Monday, November 27th. They set a buy rating and a $7.00 price target on the stock. Zacks Investment Research downgraded Ohr Pharmaceuticals from a buy rating to a hold rating in a report on Friday, October 20th.

Ohr Pharmaceuticals (NASDAQ:OHRP) opened at $0.38 on Friday. Ohr Pharmaceuticals has a twelve month low of $0.35 and a twelve month high of $2.18.

Institutional investors have recently made changes to their positions in the company. Wedbush Securities Inc. acquired a new stake in shares of Ohr Pharmaceuticals in the third quarter worth $311,000. Garrison Bradford & Associates Inc. grew its stake in shares of Ohr Pharmaceuticals by 482.4% in the third quarter. Garrison Bradford & Associates Inc. now owns 497,415 shares of the biotechnology company’s stock worth $358,000 after acquiring an additional 412,000 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Ohr Pharmaceuticals by 0.7% in the second quarter. Vanguard Group Inc. now owns 812,418 shares of the biotechnology company’s stock worth $520,000 after acquiring an additional 5,481 shares during the last quarter. Institutional investors and hedge funds own 8.25% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Ohr Pharmaceuticals (OHRP) Downgraded to “Strong Sell” at ValuEngine” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.watchlistnews.com/ohr-pharmaceuticals-ohrp-downgraded-to-strong-sell-at-valuengine/1797508.html.

About Ohr Pharmaceuticals

OHR Pharmaceutical, Inc, a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.

Receive News & Ratings for Ohr Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.